Brand Name
VTAMA
Generic Name
Tapinarof
View Brand Information FDA approval date: May 28, 2025
Classification: Aryl Hydrocarbon Receptor Agonist
Form: Cream
What is VTAMA (Tapinarof)?
VTAMA ® cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Summary: This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
An Open-label, Phase II Study to Evaluate the Clinical Efficacy and Safety of Tapinarof for Adult Patients With Palmoplantar Keratoderma
Summary: The purpose of this study is to assess adults with palmoplantar keratoderma (thickening skin layer on palms and soles) who are treated with the study drug, tapinarof. This is a naturally occuring compound used for the treatment of psoriasis. This study is being done to find out how well and safe this drug is for stopping or treating keratoderma. This study aims to investigate the positive impacts ...
Related Latest Advances
Brand Information
VTAMA (tapinarof)
1DOSAGE AND ADMINISTRATION
Apply a thin layer of VTAMA cream to affected areas once daily.
Wash hands after application, unless VTAMA cream is for treatment of the hands.
VTAMA cream is not for oral, ophthalmic, or intravaginal use.
2DOSAGE FORMS AND STRENGTHS
Cream, 1%
Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream.
3CONTRAINDICATIONS
None.
4DESCRIPTION
VTAMA (tapinarof) cream contains tapinarof as the active ingredient. Tapinarof is an aryl hydrocarbon receptor agonist.
Tapinarof is a white to pale brown powder. Chemically, tapinarof is 3, 5-dihydroxy-4-isopropyl-
Each gram of VTAMA cream for topical use contains 10 mg of tapinarof in a white to off-white cream. VTAMA cream also contains the following inactive ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, edetate disodium, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate.
5HOW SUPPLIED/STORAGE AND HANDLING
VTAMA (tapinarof) cream, 1% is a white to off-white cream. Each gram of VTAMA cream contains 10 mg of tapinarof. It is supplied in the following size:
60 g laminated tubes: NDC 81672-5051-1
Storage and Handling:
- Store at 20°C to 25°C (68°F to 77°F) excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].
- Do not freeze.
- Protect from exposure to excessive heat.
6PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (
Administration Instructions
- Instruct patients to apply VTAMA cream once daily to affected skin lesions only and avoid unaffected areas of skin.
- Advise patients to wash hands after application unless VTAMA cream is for treatment of the hands.
- Advise patients that VTAMA cream is for external use only.
Dist. by: Organon LLC, a subsidiary of
For patent information:
vIGA-AD is the trademark of Eli Lilly and Co.
© 2025 Organon group of companies. All rights reserved.
uspi-og0505-cr-2505r000
7PRINCIPAL DISPLAY PANEL
NDC 81672-5051-1
Rx only
VTAMA
(tapinarof) cream 1%
(tapinarof) cream 1%
For topical use only.
60g
8PRINCIPAL DISPLAY PANEL
NDC 81672-5051-1
Rx only
VTAMA
(tapinarof) cream 1%
(tapinarof) cream 1%
For topical use only.
60g
